Trial Profile

Long-term Safety and Efficacy Study of Ferriprox for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 12 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deferiprone (Primary)
Indications Iron overload
Focus Adverse reactions
Acronyms FIRST
Sponsors ApoPharma

Most Recent Events

18 Dec 2023 Status changed from recruiting to discontinued.
14 Nov 2019 This trial is discontinued in United Kingdom, According to European Clinical Trials Database record.
10 Jan 2019 Planned End Date changed from 1 Mar 2022 to 1 Apr 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com